Oxidative stress: A bridge between Down's syndrome and Alzheimer's disease

Neurobiology of Aging

Volumn 28, Issue 5, 2007, Pages 648-676

  Zana, Marianna ^a   Janka, Zoltán ^a   Kálmán, János ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Antioxidant therapy; Biomarkers; Central nervous system; Down's syndrome; Oxidative stress; Periphery

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BIOLOGICAL MARKER; CAROTENOID; CYANOCOBALAMIN; DONEPEZIL; ESTROGEN; FLAVONOID; FOLIC ACID; GINKGO BILOBA EXTRACT; LEVACECARNINE; MELATONIN; NONSTEROID ANTIINFLAMMATORY AGENT; PIRACETAM; POLYPHENOL; PRASTERONE; PROTEIN; PYRIDOXINE; RIBOFLAVIN; RIVASTIGMINE; SELEGILINE; SUPEROXIDE DISMUTASE; THIOCTIC ACID; UNINDEXED DRUG; VITAMIN; VITAMIN B GROUP;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DIET SUPPLEMENTATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DOWN SYNDROME; ENZYME ACTIVITY; EVIDENCE BASED PRACTICE; GENE DOSAGE; HUMAN; LIPID PEROXIDATION; META ANALYSIS; NONHUMAN; NUTRITIONAL ASSESSMENT; OXIDATION; OXIDATIVE STRESS; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TREATMENT DURATION; UPREGULATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIOXIDANTS; DOWN SYNDROME; HUMANS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 33847349325     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2006.03.008     Document Type: Review

References (384)

1. Abate C., Patel L., Rauscher III F.J., and Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. Science 249 4973 (1990) 1157-1161
2. Adamec E., Vonsattel J.P., and Nixon R.A. DNA strand breaks in Alzheimer's disease. Brain Res 849 1-2 (1999) 67-77
3. Ahlskog J.E., Uitti R.J., Low P.A., Tyce G.M., Nickander K.K., Petersen R.C., et al. No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Mov Disord 10 5 (1995) 566-573
4. Ahmed N., Ahmed U., Thornalley P.J., Hager K., Fleischer G., and Munch G. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J Neurochem 92 2 (2005) 255-263
5. Aisen P.S., Davis K.L., Berg J.D., Schafer K., Campbell K., Thomas R.G., et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 54 3 (2000) 588-593
6. Aisen P.S., Schmeidler J., and Pasinetti G.M. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 58 7 (2002) 1050-1054
7. Aksenov M., Aksenova M., Butterfield D.A., and Markesbery W.R. Oxidative modification of creatine kinase BB in Alzheimer's disease brain. J Neurochem 74 6 (2000) 2520-2527
8. Aksenov M.Y., Aksenova M.V., Butterfield D.A., Geddes J.W., and Markesbery W.R. Protein oxidation in the brain in Alzheimer's disease. Neuroscience 103 2 (2001) 373-383
9. Aksenov M.Y., Aksenova M.V., Carney J.M., and Butterfield D.A. Oxidative modification of glutamine synthetase by amyloid β peptide. Free Radic Res 27 3 (1997) 267-281
10. Andersen J.K. Oxidative stress in neurodegeneration: cause or consequence?. Nat Med 10 Suppl (2004) S18-S25
11. Anderson A.J., Stoltzner S., Lai F., Su J., and Nixon R.A. Morphological and biochemical assessment of DNA damage and apoptosis in Down syndrome and Alzheimer disease, and effect of postmortem tissue archival on TUNEL. Neurobiol Aging 21 4 (2000) 511-524
12. Anekonda T.S., and Reddy P.H. Can herbs provide a new generation of drugs for treating Alzheimer's disease?. Brain Res Brain Res Rev 50 2 (2005) 361-376
13. Ani C., Grantham-McGregor S., and Muller D. Nutritional supplementation in Down syndrome: theoretical considerations and current status. Dev Med Child Neurol 42 3 (2000) 207-213
14. Anneren G., Gardner A., and Lundin T. Increased glutathione peroxidase activity in erythrocytes in patients with Alzheimer's disease/senile dementia of Alzheimer's type. Acta Neurol Scand 73 6 (1986) 586-589
15. Anneren G., Gebre-Medhin M., and Gustavson K.H. Increased plasma and erythrocyte selenium concentrations but decreased erythrocyte glutathione peroxidase activity after selenium supplementation in children with Down syndrome. Acta Paediatr Scand 78 6 (1989) 879-884
16. Anneren K.G., and Epstein C.J. Lipid peroxidation and superoxide dismutase-1 and glutathione peroxidase activities in trisomy 16 fetal mice and human trisomy 21 fibroblasts. Pediatr Res 21 1 (1987) 88-92
17. Antila E., Nordberg U.R., Syvaoja E.L., and Westermarck T. Selenium therapy in Down syndrome (DS): a theory and a clinical trial. Adv Exp Med Biol 264 (1990) 183-186
18. Aruoma O.I., Bahorun T., and Jen L.S. Neuroprotection by bioactive components in medicinal and food plant extracts. Mutat Res 544 2-3 (2003) 203-215
19. Asahara H., Wistort P.M., Bank J.F., Bakerian R.H., and Cunningham R.P. Purification and characterization of Escherichia coli endonuclease III from the cloned nth gene. Biochemistry 28 10 (1989) 4444-4449
20. Asthana S., Craft S., Baker L.D., Raskind M.A., Birnbaum R.S., Lofgreen C.P., et al. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology 24 6 (1999) 657-677
21. Baggot P.J., Eliseo A.J., Kalamarides J.A., and Shoemaker J.D. A folate-dependent metabolite in amniotic fluid from pregnancies with normal or trisomy 21 chromosomes. Fetal Diagn Ther 21 1 (2006) 148-152
22. Balcz B., Kirchner L., Cairns N., Fountoulakis M., and Lubec G. Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J Neural Transmemb 61 Suppl (2001) 193-201
23. Baldereschi M., Di Carlo A., Lepore V., Bracco L., Maggi S., Grigoletto F., et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology 50 4 (1998) 996-1002
24. Baranano D.E., and Snyder S.H. Neural roles for heme oxygenase: contrasts to nitric oxide synthase. Proc Natl Acad Sci USA 98 20 (2001) 10996-11002
25. Barenfeld L.S., Pleskach N.M., Bildin V.N., Prokofjeva V.V., and Mikhelson V.M. Radioresistant DNA synthesis in cells of patients showing increased chromosomal sensitivity to ionizing radiation. Mutat Res 165 3 (1986) 159-164
26. Baum L., and Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J Alzheimers Dis 6 4 (2004) 367-377
27. Behl C., Skutella T., Lezoualc'h F., Post A., Widmann M., Newton C.J., et al. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol 51 4 (1997) 535-541
28. Behl C., Widmann M., Trapp T., and Holsboer F. 17-β Estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun 216 2 (1995) 473-482
29. Bennett F.C., McClelland S., Kriegsmann E.A., Andrus L.B., and Sells C.J. Vitamin and mineral supplementation in Down's syndrome. Pediatrics 72 5 (1983) 707-713
30. Benzi G., and Moretti A. Are reactive oxygen species involved in Alzheimer's disease?. Neurobiol Aging 16 4 (1995) 661-674
31. Bermejo P., Gomez-Serranillos P., Santos J., Pastor E., Gil P., and Martin-Aragon S. Determination of malonaldehyde in Alzheimer's disease: a comparative study of high-performance liquid chromatography and thiobarbituric acid test. Gerontology 43 4 (1997) 218-222
32. Bianchetti A., Rozzini R., and Trabucchi M. Effects of acetyl-l-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. Curr Med Res Opin 19 4 (2003) 350-353
33. Bidder R.T., Gray P., Newcombe R.G., Evans B.K., and Hughes M. The effects of multivitamins and minerals on children with Down syndrome. Dev Med Child Neurol 31 4 (1989) 532-537
34. Birks J., and Flicker L. Selegiline for Alzheimer's disease. Cochrane Database Syst Rev 1 (2003) CD000442
35. Birks J., Grimley E.V., and Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 4 (2002) CD003120
36. Boiteux S., Gajewski E., Laval J., and Dizdaroglu M. Substrate specificity of the Escherichia coli Fpg protein (formamidopyrimidine-DNA glycosylase): excision of purine lesions in DNA produced by ionizing radiation or photosensitization. Biochemistry 31 1 (1992) 106-110
37. Boothby L.A., and Doering P.L. Vitamin C and Vitamin E for Alzheimer's disease. Ann Pharmacother 39 12 (2005) 2073-2079
38. Bourdel-Marchasson I., Delmas-Beauvieux M.C., Peuchant E., Richard-Harston S., Decamps A., Reignier B., et al. Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 30 3 (2001) 235-241
39. Boyd-Kimball D., Sultana R., Abdul H.M., and Butterfield D.A. Gamma-glutamylcysteine ethyl ester-induced up-regulation of glutathione protects neurons against Aβ(1-42)-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. J Neurosci Res 79 5 (2005) 700-706
40. Bragin V., Chemodanova M., Dzhafarova N., Bragin I., Czerniawski J.L., and Aliev G. Integrated treatment approach improves cognitive function in demented and clinically depressed patients. Am J Alzheimers Dis Other Demen 20 1 (2005) 21-26
41. Bras A., Monteiro C., and Rueff J. Oxidative stress in trisomy 21. A possible role in cataractogenesis. Ophthalmic Paediatr Genet 10 4 (1989) 271-277
42. Breitner J.C., Welsh K.A., Helms M.J., Gaskell P.C., Gau B.A., Roses A.D., et al. Delayed onset of Alzheimer's disease with non-steroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 16 4 (1995) 523-530
43. Brooksbank B.W., and Balazs R. Superoxide dismutase, glutathione peroxidase and lipoperoxidation in Down's syndrome fetal brain. Brain Res 318 1 (1984) 37-44
44. Brown R.C., Han Z., Cascio C., and Papadopoulos V. Oxidative stress-mediated DHEA formation in Alzheimer's disease pathology. Neurobiol Aging 24 1 (2003) 57-65
45. Brugge K., Nichols S., Saitoh T., and Trauner D. Correlations of glutathione peroxidase activity with memory impairment in adults with Down syndrome. Biol Psychiatry 46 12 (1999) 1682-1689
46. Buckland P., Tidmarsh S., Spurlock G., Kaiser F., Yates M., O'Mahony G., et al. Amyloid precursor protein mRNA levels in the mononuclear blood cells of Alzheimer's and Down's patients. Brain Res Mol Brain Res 18 4 (1993) 316-320
47. Burke W.J., Roccaforte W.H., Wengel S.P., Bayer B.L., Ranno A.E., and Willcockson N.K. l-Deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 41 11 (1993) 1219-1225
48. Busciglio J., Pelsman A., Wong C., Pigino G., Yuan M., Mori H., et al. Altered metabolism of the amyloid β precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 33 5 (2002) 677-688
49. Busciglio J., and Yankner B.A. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 378 6559 (1995) 776-779
50. Bush A., and Beail N. Risk factors for dementia in people with down syndrome: issues in assessment and diagnosis. Am J Ment Retard 109 2 (2004) 83-97
51. Butterfield D., Castegna A., Pocernich C., Drake J., Scapagnini G., and Calabrese V. Nutritional approaches to combat oxidative stress in Alzheimer's disease. J Nutr Biochem 13 8 (2002) 444-461
52. Butterfield D.A. Beta-amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Chem Res Toxicol 10 5 (1997) 495-506
53. Butterfield D.A., Boyd-Kimball D., and Castegna A. Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration. J Neurochem 86 6 (2003) 1313-1327
54. Butterfield D.A., and Bush A.I. Alzheimer's amyloid beta-peptide (1-42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiol Aging 25 5 (2004) 563-568
55. Butterfield D.A., Castegna A., Lauderback C.M., and Drake J. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 23 5 (2002) 655-664
56. Butterfield D.A., Hensley K., Cole P., Subramaniam R., Aksenov M., Aksenova M., et al. Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer's disease. J Neurochem 68 6 (1997) 2451-2457
57. Butterfield D.A., Howard B.J., Yatin S., Allen K.L., and Carney J.M. Free radical oxidation of brain proteins in accelerated senescence and its modulation by N-tert-butyl-alpha-phenylnitrone. Proc Natl Acad Sci USA 94 2 (1997) 674-678
58. Butterfield D.A., and Kanski J. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech Ageing Dev 122 9 (2001) 945-962
59. Butterfield D.A., and Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 32 11 (2002) 1050-1060
60. Calabrese V., Boyd-Kimball D., Scapagnini G., and Butterfield D.A. Nitric oxide and cellular stress response in brain aging and neurodegenerative disorders: the role of vitagenes. In Vivo 18 3 (2004) 245-267
61. Calabrese V., Ravagna A., Colombrita C., Scapagnini G., Guagliano E., Calvani M., et al. Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2. J Neurosci Res 79 4 (2005) 509-521
62. Calabrese V., Scapagnini G., Ravagna A., Colombrita C., Spadaro F., Butterfield D.A., et al. Increased expression of heat shock proteins in rat brain during aging: relationship with mitochondrial function and glutathione redox state. Mech Ageing Dev 125 4 (2004) 325-335
63. Calabrese V., Stella A.M., Butterfield D.A., and Scapagnini G. Redox regulation in neurodegeneration and longevity: role of the heme oxygenase and HSP70 systems in brain stress tolerance. Antioxid Redox Signal 6 5 (2004) 895-913
64. Calabrese V., Stella A.M., Calvani M., and Butterfield D.A. Acetylcarnitine and cellular stress response: roles in nutritional redox homeostasis and regulation of longevity genes. J Nutr Biochem 17 2 (2006) 73-88
65. Camandola S., Poli G., and Mattson M.P. The lipid peroxidation product 4-hydroxy-2,3-nonenal inhibits constitutive and inducible activity of nuclear factor kappa B in neurons. Brain Res Mol Brain Res 85 1-2 (2000) 53-60
66. Cameron D.R., and Braunstein G.D. The use of dehydroepiandrosterone therapy in clinical practice. Treat Endocrinol 4 2 (2005) 95-114
67. Capone G.T. Down syndrome: advances in molecular biology and the neurosciences. J Dev Behav Pediatr 22 1 (2001) 40-59
68. Cardoso S.M., Proenca M.T., Santos S., Santana I., and Oliveira C.R. Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol Aging 25 1 (2004) 105-110
69. Castegna A., Aksenov M., Aksenova M., Thongboonkerd V., Klein J.B., Pierce W.M., et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I. Creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med 33 4 (2002) 562-571
70. Castegna A., Aksenov M., Thongboonkerd V., Klein J.B., Pierce W.M., Booze R., et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II. Dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 82 6 (2002) 1524-1532
71. Cattabeni F., Colciaghi F., and Di Luca M. Platelets provide human tissue to unravel pathogenic mechanisms of Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry 28 5 (2004) 763-770
72. Ceballos-Picot I., Merad-Boudia M., Nicole A., Thevenin M., Hellier G., Legrain S., et al. Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer's type-place of the extracellular glutathione peroxidase. Free Radic Biol Med 20 4 (1996) 579-587
73. Cecchi C., Fiorillo C., Sorbi S., Latorraca S., Nacmias B., Bagnoli S., et al. Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients. Free Radic Biol Med 33 10 (2002) 1372-1379
74. Chaney M.O., Stine W.B., Kokjohn T.A., Kuo Y.M., Esh C., Rahman A., et al. RAGE and amyloid β interactions: atomic force microscopy and molecular modeling. Biochim Biophys Acta 1741 1-2 (2005) 199-205
75. Cheon M.S., Shim K.S., Kim S.H., Hara A., and Lubec G. Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: challenging the gene dosage effect hypothesis (Part IV). Amino Acids 25 1 (2003) 41-47
76. Cherubini A., Martin A., Andres-Lacueva C., Di Iorio A., Lamponi M., Mecocci P., et al. Vitamin E levels, cognitive impairment and dementia in older persons: the InCHIANTI study. Neurobiol Aging 26 7 (2005) 987-994
77. Chiueh C.C. Neuroprotective properties of nitric oxide. Ann NY Acad Sci 890 (1999) 301-311
78. Choi J., Malakowsky C.A., Talent J.M., Conrad C.C., and Gracy R.W. Identification of oxidized plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 293 5 (2002) 1566-1570
79. Choi J., Rees H.D., Weintraub S.T., Levey A.I., Chin L.S., and Li L. Oxidative modifications and aggregation of Cu, Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J Biol Chem 280 12 (2005) 11648-11655
80. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr 71 2 (2000) 621S-629S
81. Clarke R., Harrison G., and Richards S. Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. J Intern Med 254 1 (2003) 67-75
82. Colciaghi F., Marcello E., Borroni B., Zimmermann M., Caltagirone C., Cattabeni F., et al. Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology 62 3 (2004) 498-501
83. Collins A.R. Oxidative DNA damage, antioxidants, and cancer. Bioessays 21 3 (1999) 238-246
84. Colurso G.J., Nilson J.E., and Vervoort L.G. Quantitative assessment of DNA fragmentation and β-amyloid deposition in insular cortex and midfrontal gyrus from patients with Alzheimer's disease. Life Sci 73 14 (2003) 1795-1803
85. Craft N.E., Haitema T.B., Garnett K.M., Fitch K.A., and Dorey C.K. Carotenoid, tocopherol, and retinol concentrations in elderly human brain. J Nutr Health Aging 8 3 (2004) 156-162
86. Croisile B., Trillet M., Fondarai J., Laurent B., Mauguiere F., and Billardon M. Long-term and high-dose piracetam treatment of Alzheimer's disease. Neurology 43 2 (1993) 301-305
87. Crosti N., Bajer J., Gentile M., Resta G., and Serra A. Catalase and glutathione peroxidase activity in cells with trisomy 21. Clin Genet 36 2 (1989) 107-116
88. Cummings B.J. Plaques and tangles: searching for primary events in a forest of data. Neurobiol Aging 18 4 (1997) 358-362
89. Davydov V., Hansen L.A., and Shackelford D.A. Is DNA repair compromised in Alzheimer's disease?. Neurobiol Aging 24 7 (2003) 953-968
90. Dawson V.L., and Dawson T.M. Nitric oxide in neurodegeneration. Prog Brain Res 118 (1998) 215-229
91. De Falco F.A., D'Angelo E., Grimaldi G., Scafuro F., Sachez F., and Caruso G. Effect of the chronic treatment with l-acetylcarnitine in Down's syndrome. Clin Ter 144 2 (1994) 123-127
92. de Haan J.B., Cristiano F., Iannello R.C., and Kola I. Cu/Zn-superoxide dismutase and glutathione peroxidase during aging. Biochem Mol Biol Int 35 6 (1995) 1281-1297
93. de la Monte S.M., Luong T., Neely T.R., Robinson D., and Wands J.R. Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease. Lab Invest 80 8 (2000) 1323-1335
94. de las C.N., Munoz U., Hermida O.G., and Martin-Requero A. Altered transcriptional regulators in response to serum in immortalized lymphocytes from Alzheimer's disease patients. Neurobiol Aging 26 5 (2005) 615-624
95. De Meyer G.R., De Cleen D.M., Cooper S., Knaapen M.W., Jans D.M., Martinet W., et al. Platelet phagocytosis and processing of β-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis. Circ Res 90 11 (2002) 1197-1204
96. DeFeudis F.V., Papadopoulos V., and Drieu K. Ginkgo biloba extracts and cancer: a research area in its infancy. Fundam Clin Pharmacol 17 4 (2003) 405-417
97. Deng J., Zhou D.H., Li J., John W.Y., Gao C., and Chen M. A 2-year follow-up study of alcohol consumption and risk of dementia. Clin Neurol Neurosurg (2005)
98. Di Luca M., Pastorino L., Bianchetti A., Perez J., Vignolo L.A., Lenzi G.L., et al. Differential level of platelet amyloid β precursor protein isoforms: an early marker for Alzheimer disease. Arch Neurol 55 9 (1998) 1195-1200
99. Di Luca M., Pastorino L., Cattabeni F., Zanardi R., Scarone S., Racagni G., et al. Abnormal pattern of platelet APP isoforms in Alzheimer disease and Down syndrome. Arch Neurol 53 11 (1996) 1162-1166
100. Dizdaroglu M. Oxidative damage to DNA in mammalian chromatin. Mutat Res 275 3-6 (1992) 331-342
101. Donfrancesco R., and Dell'uomo A. Ginkgo biloba in Down syndrome. Phytomedicine 11 6 (2004) 469
102. Doody R.S., Stevens J.C., Beck C., Dubinsky R.M., Kaye J.A., Gwyther L., et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56 9 (2001) 1154-1166
103. Drake J., Kanski J., Varadarajan S., Tsoras M., and Butterfield D.A. Elevation of brain glutathione by gamma-glutamylcysteine ethyl ester protects against peroxynitrite-induced oxidative stress. J Neurosci Res 68 6 (2002) 776-784
104. Drake J., Petroze R., Castegna A., Ding Q., Keller J.N., Markesbery W.R., et al. 4-Hydroxynonenal oxidatively modifies histones: implications for Alzheimer's disease. Neurosci Lett 356 3 (2004) 155-158
105. Druzhyna N., Nair R.G., LeDoux S.P., and Wilson G.L. Defective repair of oxidative damage in mitochondrial DNA in Down's syndrome. Mutat Res 409 2 (1998) 81-89
106. Du Y.S., Zhu H., Fu J., Yan S.F., Roher A., Tourtellotte W.W., et al. Amyloid-β peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA 94 10 (1997) 5296-5301
107. Ellinson M., Thomas J., and Patterson A. A critical evaluation of the relationship between serum Vitamin B, folate and total homocysteine with cognitive impairment in the elderly. J Hum Nutr Diet 17 4 (2004) 371-383
108. Engelhart M.J., Geerlings M.I., Ruitenberg A., van Swieten J.C., Hofman A., Witteman J.C., et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287 24 (2002) 3223-3229
109. Engelhart M.J., Ruitenberg A., Meijer J., Kiliaan A., van Swieten J.C., Hofman A., et al. Plasma levels of antioxidants are not associated with Alzheimer's disease or cognitive decline. Dement Geriatr Cogn Disord 19 2-3 (2005) 134-139
110. Engidawork E., Balic N., Juranville J.F., Fountoulakis M., Dierssen M., and Lubec G. Unaltered expression of Fas (CD95/APO-1), caspase-3, Bcl-2 and annexins in brains of fetal Down syndrome: evidence against increased apoptosis. J Neural Transm 61 Suppl (2001) 149-162
111. Etminan M., Gill S., and Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 327 7407 (2003) 128-132
112. Farr S.A., Poon H.F., Dogrukol-Ak D., Drake J., Banks W.A., Eyerman E., et al. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem 84 5 (2003) 1173-1183
113. Feng Z., Chang Y., Cheng Y., Zhang B.L., Qu Z.W., Qin C., et al. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J Pineal Res 37 2 (2004) 129-136
114. Filip V., and Kolibas E. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. J Psychiatry Neurosci 24 3 (1999) 234-243
115. Fillenbaum G.G., Kuchibhatla M.N., Hanlon J.T., Artz M.B., Pieper C.F., Schmader K.E., et al. Dementia and Alzheimer's Disease in Community-Dwelling Elders Taking Vitamin C and/or Vitamin E. Ann Pharmacother 39 12 (2005) 2009-2014
116. Fillon-Emery N., Chango A., Mircher C., Barbe F., Blehaut H., Herbeth B., et al. Homocysteine concentrations in adults with trisomy 21: effect of B vitamins and genetic polymorphisms. Am J Clin Nutr 80 6 (2004) 1551-1557
117. Flicker L., and Grimley E.G. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev 2 (2001) CD001011
118. Folin M., Baiguera S., Conconi M.T., Pati T., Grandi C., Parnigotto P.P., et al. The impact of risk factors of Alzheimer's disease in the Down syndrome. Int J Mol Med 11 2 (2003) 267-270
119. Fourrier A., Letenneur L., Begaud B., and Dartigues J.F. Non-steroidal antiinflammatory drug use and cognitive function in the elderly: inconclusive results from a population-based cohort study. J Clin Epidemiol 49 10 (1996) 1201
120. Freedman M., Rewilak D., Xerri T., Cohen S., Gordon A.S., Shandling M., et al. l-Deprenyl in Alzheimer's disease: cognitive and behavioral effects. Neurology 50 3 (1998) 660-668
121. Gabbita S.P., Lovell M.A., and Markesbery W.R. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem 71 5 (1998) 2034-2040
122. Gabryel B., and Trzeciak H.I. Nootropics: pharmacological properties and therapeutic use. Pol J Pharmacol 46 5 (1994) 383-394
123. Gadhia P., Gadhia M., and Zankl H. Effects of bleomycin on Down's syndrome lymphocytes in culture. Mutat Res 207 3-4 (1988) 153-158
124. Gadhia P., Gadhia M., and Zankl H. Adriamycin-induced sister chromatid exchange and chromosomal aberrations in Down's syndrome lymphocytes. Mutagenesis 6 1 (1991) 31-33
125. Gale C.R., Martyn C.N., and Cooper C. Cognitive impairment and mortality in a cohort of elderly people. BMJ 312 7031 (1996) 608-611
126. Ganguli M., Chandra V., Kamboh M.I., Johnston J.M., Dodge H.H., Thelma B.K., et al. Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US Cross-National Dementia Study. Arch Neurol 57 6 (2000) 824-830
127. Garcia A., and Zanibbi K. Homocysteine and cognitive function in elderly people. CMAJ 171 8 (2004) 897-904
128. Genedani S., Rasio G., Cortelli P., Antonelli F., Guidolin D., Galantucci M., et al. Studies on homocysteine and dehydroepiandrosterone sulphate plasma levels in Alzheimer's disease patients and in Parkinson's disease patients. Neurotox Res 6 4 (2004) 327-332
129. Gibbs R.B. Estrogen and nerve growth factor-related systems in brain. Effects on basal forebrain cholinergic neurons and implications for learning and memory processes and aging. Ann NY Acad Sci 743 (1994) 165-196
130. Gillman M.W., Cupples L.A., Gagnon D., Posner B.M., Ellison R.C., Castelli W.P., et al. Protective effect of fruits and vegetables on development of stroke in men. JAMA 273 14 (1995) 1113-1117
131. Girones X., Guimera A., Cruz-Sanchez C.Z., Ortega A., Sasaki N., Makita Z., et al. N epsilon-carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease. Free Radic Biol Med 36 10 (2004) 1241-1247
132. Good P.F., Werner P., Hsu A., Olanow C.W., and Perl D.P. Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol 149 1 (1996) 21-28
133. Govoni S., Bergamaschi S., Gasparini L., Quaglia C., Racchi M., Cattaneo E., et al. Fibroblasts of patients affected by Down's syndrome oversecrete amyloid precursor protein and are hyporesponsive to protein kinase C stimulation. Neurology 47 4 (1996) 1069-1075
134. Gromadzinska J., Wasowicz W., Sklodowska M., and Strozynski H. Glutathione peroxidase activity, lipid peroxides and selenium status in blood in patients with Down's syndrome. J Clin Chem Clin Biochem 26 5 (1988) 255-258
135. Growdon J.H., Corkin S., Huff F.J., and Rosen T.J. Piracetam combined with lecithin in the treatment of Alzheimer's disease. Neurobiol Aging 7 4 (1986) 269-276
136. Gsell W., Conrad R., Hickethier M., Sofic E., Frolich L., Wichart I., et al. Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem 64 3 (1995) 1216-1223
137. Gualandri W., Gualandri L., Demartini G., Esposti R., Marthyn P., Volonte S., et al. Redox balance in patients with Down's syndrome before and after dietary supplementation with alpha-lipoic acid and l-cysteine. Int J Clin Pharmacol Res 23 1 (2003) 23-30
138. Guidi I., Galimberti D., Lonati S., Novembrino C., Bamonti F., Tiriticco M., et al. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 27 2 (2006) 262-269
139. Gulesserian T., Engidawork E., Fountoulakis M., and Lubec G. Antioxidant proteins in fetal brain: superoxide dismutase-1 (SOD-1) protein is not overexpressed in fetal Down syndrome. J Neural Transm 61 Suppl (2001) 71-84
140. Gulesserian T., Seidl R., Hardmeier R., Cairns N., and Lubec G. Superoxide dismutase SOD1, encoded on chromosome 21, but not SOD2 is overexpressed in brains of patients with Down syndrome. J Investig Med 49 1 (2001) 41-46
141. Gutteridge J.M. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 41 12 Pt 2 (1995) 1819-1828
142. Hayn M., Kremser K., Singewald N., Cairns N., Nemethova M., Lubec B., et al. Evidence against the involvement of reactive oxygen species in the pathogenesis of neuronal death in Down's syndrome and Alzheimer's disease. Life Sci 59 7 (1996) 537-544
143. Head E., Garzon-Rodriguez W., Johnson J.K., Lott I.T., Cotman C.W., and Glabe C. Oxidation of Aβ and plaque biogenesis in Alzheimer's disease and Down syndrome. Neurobiol Dis 8 5 (2001) 792-806
144. Head E., and Lott I.T. Down syndrome and beta-amyloid deposition. Curr Opin Neurol 17 2 (2004) 95-100
145. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 9326 (2002) 23-33
146. Hensley K., Hall N., Subramaniam R., Cole P., Harris M., Aksenov M., et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 65 5 (1995) 2146-2156
147. Hensley K., Maidt M.L., Yu Z., Sang H., Markesbery W.R., and Floyd R.A. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 18 20 (1998) 8126-8132
148. Hermon M., Cairns N., Egly J.M., Fery A., Labudova O., and Lubec G. Expression of DNA excision-repair-cross-complementing proteins p80 and p89 in brain of patients with Down syndrome and Alzheimer's disease. Neurosci Lett 251 1 (1998) 45-48
149. Hirai K., Aliev G., Nunomura A., Fujioka H., Russell R.L., Atwood C.S., et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21 9 (2001) 3017-3023
150. Ho P.I., Ashline D., Dhitavat S., Ortiz D., Collins S.C., Shea T.B., et al. Folate deprivation induces neurodegeneration: roles of oxidative stress and increased homocysteine. Neurobiol Dis 14 1 (2003) 32-42
151. Hogervorst E., Williams J., Budge M., Riedel W., and Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience 101 3 (2000) 485-512
152. Hogervorst E., Williams J., Combrinck M., and David S.A. Measuring serum oestradiol in women with Alzheimer's disease: the importance of the sensitivity of the assay method. Eur J Endocrinol 148 1 (2003) 67-72
153. Hopkins W.E., Fukagawa N.K., Sobel B.E., and Schneider D.J. Plasminogen activator inhibitor type 1 in adults with Down syndrome and protection against macrovascular disease. Am J Cardiol 85 6 (2000) 784-786
154. Howes M.J., and Houghton P.J. Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacol Biochem Behav 75 3 (2003) 513-527
155. Hudson S., and Tabet N. Acetyl-l-carnitine for dementia. Cochrane Database Syst Rev 2 (2003) CD003158
156. in t' Veld B.A., Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., et al. Non-steroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345 21 (2001) 1515-1521
157. Isacson O., Seo H., Lin L., Albeck D., and Granholm A.C. Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. Trends Neurosci 25 2 (2002) 79-84
158. Iwatsubo T., Mann D.M., Odaka A., Suzuki N., and Ihara Y. Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. Ann Neurol 37 3 (1995) 294-299
159. Jaffe A.B., Toran-Allerand C.D., Greengard P., and Gandy S.E. Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J Biol Chem 269 18 (1994) 13065-13068
160. Jansen S., Duncan V., and Morgan D. Melatonin for cognitive impairment. Cochrane Database Syst Rev 1 (2006) CD003802
161. Joseph J.A., Shukitt-Hale B., and Casadesus G. Reversing the deleterious effects of aging on neuronal communication and behavior: beneficial properties of fruit polyphenolic compounds. Am J Clin Nutr 81 1 Suppl (2005) 313S-316S
162. Joshi G., Perluigi M., Sultana R., Agrippino R., Calabrese V., and Butterfield D.A. In vivo protection of synaptosomes by ferulic acid ethyl ester (FAEE) from oxidative stress mediated by 2,2-azobis(2-amidino-propane)dihydrochloride (AAPH) or Fe(2+)/H(2)O(2): Insight into mechanisms of neuroprotection and relevance to oxidative stress-related neurodegenerative disorders. Neurochem Int 48 4 (2006) 318-327
163. Jovanovic S.V., Clements D., and MacLeod K. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic Biol Med 25 9 (1998) 1044-1048
164. Kadioglu E., Sardas S., Aslan S., Isik E., and Esat K.A. Detection of oxidative DNA damage in lymphocytes of patients with Alzheimer's disease. Biomarkers 9 2 (2004) 203-209
165. Kalman J., Dey I., Ilona S.V., Matkovics B., Brown D., Janka Z., et al. Platelet membrane fluidity and plasma malondialdehyde levels in Alzheimer's demented patients with and without family history of dementia. Biol Psychiatry 35 3 (1994) 190-194
166. Kanowski S., Herrmann W.M., Stephan K., Wierich W., and Horr R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 29 2 (1996) 47-56
167. Kanowski S., and Hoerr R. Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry 36 6 (2003) 297-303
168. Karelson E., Bogdanovic N., Garlind A., Winblad B., Zilmer K., Kullisaar T., et al. The cerebrocortical areas in normal brain aging and in Alzheimer's disease: noticeable differences in the lipid peroxidation level and in antioxidant defense. Neurochem Res 26 4 (2001) 353-361
169. Kawamoto E.M., Munhoz C.D., Glezer I., Bahia V.S., Caramelli P., Nitrini R., et al. Oxidative state in platelets and erythrocytes in aging and Alzheimer's disease. Neurobiol Aging 26 6 (2005) 857-864
170. Kelloff G.J., Crowell J.A., Steele V.E., Lubet R.A., Malone W.A., Boone C.W., et al. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 130 2S Suppl (2000) 467S-471S
171. Kim S.H., Vlkolinsky R., Cairns N., and Lubec G. Decreased levels of complex III core protein 1 and complex V beta chain in brains from patients with Alzheimer's disease and Down syndrome. Cell Mol Life Sci 57 12 (2000) 1810-1816
172. Kirsch M., and De Groot H. NAD(P)H, a directly operating antioxidant?. FASEB J 15 9 (2001) 1569-1574
173. Korenberg J.R., Kawashima H., Pulst S.M., Ikeuchi T., Ogasawara N., Yamamoto K., et al. Molecular definition of a region of chromosome 21 that causes features of the Down syndrome phenotype. Am J Hum Genet 47 2 (1990) 236-246
174. Krasuski J.S., Alexander G.E., Horwitz B., Rapoport S.I., and Schapiro M.B. Relation of medial temporal lobe volumes to age and memory function in non-demented adults with Down's syndrome: implications for the prodromal phase of Alzheimer's disease. Am J Psychiatry 159 1 (2002) 74-81
175. Kuo H.K., Sorond F.A., Chen J.H., Hashmi A., Milberg W.P., and Lipsitz L.A. The role of homocysteine in multisystem age-related problems: a systematic review. J Gerontol A Biol Sci Med Sci 60 9 (2005) 1190-1201
176. Kurobe N., Suzuki F., Okajima K., and Kato K. Sensitive enzyme immunoassay for human Cu/Zn superoxide dismutase. Clin Chim Acta 187 1 (1990) 11-20
177. Lambert B., Hansson K., Bui T.H., Funes-Cravioto F., and Lindsten J. DNA repair and frequency of X-ray and UV-light induced chromosome aberrations in leukocytes from patients with Down's syndrome. Ann Hum Genet 39 3 (1976) 293-303
178. Laurin D., Masaki K.H., Foley D.J., White L.R., and Launer L.J. Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu-Asia Aging Study. Am J Epidemiol 159 10 (2004) 959-967
179. Le Bars P.L. Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles. Pharmacopsychiatry 36 Suppl 1 (2003) S50-S55
180. Le Bars P.L., Katz M.M., Berman N., Itil T.M., Freedman A.M., and Schatzberg A.F. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 278 16 (1997) 1327-1332
181. Le Bars P.L., Velasco F.M., Ferguson J.M., Dessain E.C., Kieser M., and Hoerr R. Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba extract EGb 761 in Alzheimer's disease. Neuropsychobiology 45 1 (2002) 19-26
182. Leboeuf R. Homocysteine and Alzheimer's disease. J Am Diet Assoc 103 3 (2003) 304-307
183. Ledesma M.D., Bonay P., Colaco C., and Avila J. Analysis of microtubule-associated protein tau glycation in paired helical filaments. J Biol Chem 269 34 (1994) 21614-21619
184. Leonard J.C., and Merz T. Repair of single-strand breaks in normal and trisomic lymphocytes. Mutat Res 105 6 (1982) 417-422
185. Leverenz J.B., and Raskind M.A. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol 150 2 (1998) 296-304
186. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., and Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21 21 (2001) 8370-8377
187. Liu H., Harrell L.E., Shenvi S., Hagen T., and Liu R.M. Gender differences in glutathione metabolism in Alzheimer's disease. J Neurosci Res 79 6 (2005) 861-867
188. Liu J., and Ames B.N. Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease. Nutr Neurosci 8 2 (2005) 67-89
189. Liu R.H. Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicals. Am J Clin Nutr 78 3 Suppl (2003) 517S-520S
190. Lobaugh N.J., Karaskov V., Rombough V., Rovet J., Bryson S., Greenbaum R., et al. Piracetam therapy does not enhance cognitive functioning in children with down syndrome. Arch Pediatr Adolesc Med 155 4 (2001) 442-448
191. Lott I.T., and Head E. Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging 26 3 (2005) 383-389
192. Lovell M.A., Ehmann W.D., Butler S.M., and Markesbery W.R. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45 8 (1995) 1594-1601
193. Lovell M.A., Gabbita S.P., and Markesbery W.R. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J Neurochem 72 2 (1999) 771-776
194. Lovell M.A., Xie C., and Markesbery W.R. Decreased base excision repair and increased helicase activity in Alzheimer's disease brain. Brain Res 855 1 (2000) 116-123
195. Lovell M.A., Xie C., Xiong S., and Markesbery W.R. Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid. J Alzheimers Dis 5 3 (2003) 229-239
196. Luchsinger J.A., and Mayeux R. Dietary factors and Alzheimer's disease. Lancet Neurol 3 10 (2004) 579-587
197. Luchsinger J.A., Tang M.X., Shea S., and Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 60 2 (2003) 203-208
198. Luchsinger J.A., Tang M.X., Siddiqui M., Shea S., and Mayeux R. Alcohol intake and risk of dementia. J Am Geriatr Soc 52 4 (2004) 540-546
199. Lyras L., Cairns N.J., Jenner A., Jenner P., and Halliwell B. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. J Neurochem 68 5 (1997) 2061-2069
200. Maki P.M., and Resnick S.M. Effects of estrogen on patterns of brain activity at rest and during cognitive activity: a review of neuroimaging studies. Neuroimage 14 4 (2001) 789-801
201. 12 and folate in vascular dementia and in Alzheimer disease. Clin Chem Lab Med 42 9 (2004) 1032-1035
202. 12 for cognition and dementia. Cochrane Database Syst Rev 4 (2003) CD004514
203. 12 for cognition. Cochrane Database Syst Rev 3 (2003) CD004326
204. 6 on cognition. Cochrane Database Syst Rev 4 (2003) CD004393
205. Maluf S.W., and Erdtmann B. Genomic instability in Down syndrome and Fanconi anemia assessed by micronucleus analysis and single-cell gel electrophoresis. Cancer Genet Cytogenet 124 1 (2001) 71-75
206. Marcus D.L., Thomas C., Rodriguez C., Simberkoff K., Tsai J.S., Strafaci J.A., et al. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol 150 1 (1998) 40-44
207. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23 1 (1997) 134-147
208. Markesbery W.R., and Lovell M.A. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19 1 (1998) 33-36
209. Martin-Aragon S., Benedi J.M., and Villar A.M. Modifications on antioxidant capacity and lipid peroxidation in mice under fraxetin treatment. J Pharm Pharmacol 49 1 (1997) 49-52
210. Martins R.N., Muir J., Brooks W.S., Creasey H., Montgomery P., Sellers P., et al. Plasma amyloid precursor protein is decreased in Alzheimer's disease. Neuroreport 4 6 (1993) 757-759
211. Mates J.M., Perez-Gomez C., and Nunez dC I. Antioxidant enzymes and human diseases. Clin Biochem 32 8 (1999) 595-603
212. Maxwell C.J., Hicks M.S., Hogan D.B., Basran J., and Ebly E.M. Supplemental use of antioxidant vitamins and subsequent risk of cognitive decline and dementia. Dement Geriatr Cogn Disord 20 1 (2005) 45-51
213. Mazeh D., Cholostoy A., Zemishlani C., and Barak Y. Elderly psychiatric patients at risk of folic acid deficiency: a case controlled study. Arch Gerontol Geriatr 41 3 (2005) 297-302
214. McDaniel M.A., Maier S.F., and Einstein G.O. "Brain-specific" nutrients: a memory cure?. Nutrition 19 11-12 (2003) 957-975
215. Mecocci P., Polidori M.C., Cherubini A., Ingegni T., Mattioli P., Catani M., et al. Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch Neurol 59 5 (2002) 794-798
216. Mecocci P., Polidori M.C., Ingegni T., Cherubini A., Chionne F., Cecchetti R., et al. Oxidative damage to DNA in lymphocytes from AD patients. Neurology 51 4 (1998) 1014-1017
217. Mehta P.D., Mehta S.P., Fedor B., Patrick B.A., Emmerling M., and Dalton A.J. Plasma amyloid beta protein 1-42 levels are increased in old Down syndrome but not in young Down syndrome. Neurosci Lett 342 3 (2003) 155-158
218. Melaragno M.I., Smith M.A., Kormann-Bortolotto M.H., and Toniolo Neto J.T. Lymphocyte proliferation and sister chromatid exchange in Alzheimer's disease. Gerontology 37 6 (1991) 293-298
219. Menendez M. Down syndrome, Alzheimer's disease and seizures. Brain Dev 27 4 (2005) 246-252
220. Midorikawa K., and Kawanishi S. Superoxide dismutases enhance H2O2-induced DNA damage and alter its site specificity. FEBS Lett 495 3 (2001) 187-190
221. Migliore L., Fontana I., Colognato R., Coppede F., Siciliano G., and Murri L. Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Neurobiol Aging 26 5 (2005) 587-595
222. Migliore L., Fontana I., Trippi F., Colognato R., Coppede F., Tognoni G., et al. Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging 26 5 (2005) 567-573
223. 6, and vascular disease in AD patients. Neurology 58 10 (2002) 1471-1475
224. Misonou H., Morishima-Kawashima M., and Ihara Y. Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. Biochemistry 39 23 (2000) 6951-6959
225. Miyata T., Inagi R., Asahi K., Yamada Y., Horie K., Sakai H., et al. Generation of protein carbonyls by glycoxidation and lipoxidation reactions with autoxidation products of ascorbic acid and polyunsaturated fatty acids. FEBS Lett 437 1-2 (1998) 24-28
226. 6 and folate intake in AD and healthy aging. J Nutr Health Aging 7 3 (2003) 160-165
227. Montgomery S.A., Thal L.J., and Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-l-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol 18 2 (2003) 61-71
228. Montine K.S., Quinn J.F., Zhang J., Fessel J.P., Roberts L.J., Morrow J.D., et al. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids 128 1-2 (2004) 117-124
229. Montine T.J., Quinn J.F., Milatovic D., Silbert L.C., Dang T., Sanchez S., et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol 52 2 (2002) 175-179
230. Moreira P.I., Honda K., Zhu X., Nunomura A., Casadesus G., Smith M.A., et al. Brain and brawn. Parallels in oxidative strength. Neurology (2005)
231. Morocz M., Kalman J., Juhasz A., Sinko I., McGlynn A.P., Downes C.S., et al. Elevated levels of oxidative DNA damage in lymphocytes from patients with Alzheimer's disease. Neurobiol Aging 23 1 (2002) 47-53
232. Morris M.C., Evans D.A., Bienias J.L., Scherr P.A., Tangney C.C., Hebert L.E., et al. Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline. J Neurol Neurosurg Psychiatry 75 8 (2004) 1093-1099
233. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Bennett D.A., Aggarwal N., et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 287 24 (2002) 3230-3237
234. Morris M.C., Evans D.A., Tangney C.C., Bienias J.L., Wilson R.S., Aggarwal N.T., et al. Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. Am J Clin Nutr 81 2 (2005) 508-514
235. Mruthinti S., Buccafusco J.J., Hill W.D., Waller J.L., Jackson T.W., Zamrini E.Y., et al. Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging 25 8 (2004) 1023-1032
236. Muchova J., Sustrova M., Garaiova I., Liptakova A., Blazicek P., Kvasnicka P., et al. Influence of age on activities of antioxidant enzymes and lipid peroxidation products in erythrocytes and neutrophils of Down syndrome patients. Free Radic Biol Med 31 4 (2001) 499-508
237. Mukamal K.J., Kuller L.H., Fitzpatrick A.L., Longstreth Jr. W.T., Mittleman M.A., and Siscovick D.S. Prospective study of alcohol consumption and risk of dementia in older adults. JAMA 289 11 (2003) 1405-1413
238. Mullaart E., Boerrigter M.E., Ravid R., Swaab D.F., and Vijg J. Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients. Neurobiol Aging 11 3 (1990) 169-173
239. Mulnard R.A., Corrada M.M., and Kawas C.H. Estrogen replacement therapy, Alzheimer's disease, and mild cognitive impairment. Curr Neurol Neurosci Rep 4 5 (2004) 368-373
240. Mulnard R.A., Cotman C.W., Kawas C., van Dyck C.H., Sano M., Doody R., et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 283 8 (2000) 1007-1015
241. Munch G., Kuhla B., Luth H.J., Arendt T., and Robinson S.R. Anti-ageing defences against Alzheimer's disease. Biochem Soc Trans 31 Pt 6 (2003) 1397-1399
242. Munch G., Thome J., Foley P., Schinzel R., and Riederer P. Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res Brain Res Rev 23 1-2 (1997) 134-143
243. Nawata H., Yanase T., Goto K., Okabe T., Nomura M., Ashida K., et al. Adrenopause. Horm Res 62 Suppl 3 (2004) 110-114
244. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60 8 (2001) 759-767
245. Nunomura A., Perry G., Pappolla M.A., Friedland R.P., Hirai K., Chiba S., et al. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol 59 11 (2000) 1011-1017
246. Nunomura A., Perry G., Pappolla M.A., Wade R., Hirai K., Chiba S., et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 19 6 (1999) 1959-1964
247. Odetti P., Angelini G., Dapino D., Zaccheo D., Garibaldi S., Dagna-Bricarelli F., et al. Early glycoxidation damage in brains from Down's syndrome. Biochem Biophys Res Commun 243 3 (1998) 849-851
248. Ohkura T., Isse K., Akazawa K., Hamamoto M., Yaoi Y., and Hagino N. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: seven case reports. Dementia 6 2 (1995) 99-107
249. Okabe T., Hamaguchi K., Inafuku T., and Hara M. Aging and superoxide dismutase activity in cerebrospinal fluid. J Neurol Sci 141 1-2 (1996) 100-104
250. Oken B.S., Storzbach D.M., and Kaye J.A. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 55 11 (1998) 1409-1415
251. Ono K., Hasegawa K., Naiki H., and Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 75 6 (2004) 742-750
252. Ono K., Yoshiike Y., Takashima A., Hasegawa K., Naiki H., and Yamada M. Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro. Exp Neurol 189 2 (2004) 380-392
253. Padovani A., Borroni B., Colciaghi F., Pettenati C., Cottini E., Agosti C., et al. Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. Arch Neurol 59 1 (2002) 71-75
254. Paganini-Hill A., and Henderson V.W. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 156 19 (1996) 2213-2217
255. Pallister C., Jung S.S., Shaw I., Nalbantoglu J., Gauthier S., and Cashman N.R. Lymphocyte content of amyloid precursor protein is increased in Down's syndrome and aging. Neurobiol Aging 18 1 (1997) 97-103
256. Pastor M.C., Sierra C., Dolade M., Navarro E., Brandi N., Cabre E., et al. Antioxidant enzymes and fatty acid status in erythrocytes of Down's syndrome patients. Clin Chem 44 5 (1998) 924-929
257. Pastore A., Tozzi G., Gaeta L.M., Giannotti A., Bertini E., Federici G., et al. Glutathione metabolism and antioxidant enzymes in children with Down syndrome. J Pediatr 142 5 (2003) 583-585
258. Pelsman A., Hoyo-Vadillo C., Gudasheva T.A., Seredenin S.B., Ostrovskaya R.U., and Busciglio J. GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neurons. Int J Dev Neurosci 21 3 (2003) 117-124
259. Percy M.E., Dalton A.J., Markovic V.D., McLachlan D.R., Hummel J.T., Rusk A.C., et al. Red cell superoxide dismutase, glutathione peroxidase and catalase in Down syndrome patients with and without manifestations of Alzheimer disease. Am J Med Genet 35 4 (1990) 459-467
260. Perrin R., Briancon S., Jeandel C., Artur Y., Minn A., Penin F., et al. Blood activity of Cu/Zn superoxide dismutase, glutathione peroxidase and catalase in Alzheimer's disease: a case-control study. Gerontology 36 5-6 (1990) 306-313
261. Petersen R.C., Thomas R.G., Grundman M., Bennett D., Doody R., Ferris S., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352 23 (2005) 2379-2388
262. Petronis A. Alzheimer's disease and down syndrome: from meiosis to dementia. Exp Neurol 158 2 (1999) 403-413
263. Pincheira J., Navarrete M.H., de la T.C., Tapia G., and Santos M.J. Effect of Vitamin E on chromosomal aberrations in lymphocytes from patients with Down's syndrome. Clin Genet 55 3 (1999) 192-197
264. Planas M., Conde M., Audivert S., Perez-Portabella C., Burgos R., Chacon P., et al. Micronutrient supplementation in mild Alzheimer disease patients. Clin Nutr 23 2 (2004) 265-272
265. Pocernich C.B., and Butterfield D.A. Acrolein inhibits NADH-linked mitochondrial enzyme activity: implications for Alzheimer's disease. Neurotox Res 5 7 (2003) 515-520
266. Pogribna M., Melnyk S., Pogribny I., Chango A., Yi P., and James S.J. Homocysteine metabolism in children with Down syndrome: in vitro modulation. Am J Hum Genet 69 1 (2001) 88-95
267. Poon H.F., Farr S.A., Thongboonkerd V., Lynn B.C., Banks W.A., Morley J.E., et al. Proteomic analysis of specific brain proteins in aged SAMP8 mice treated with alpha-lipoic acid: implications for aging and age-related neurodegenerative disorders. Neurochem Int 46 2 (2005) 159-168
268. Porstmann T., Wietschke R., Schmechta H., Grunow R., Porstmann B., Bleiber R., et al. A rapid and sensitive enzyme immunoassay for Cu/Zn superoxide dismutase with polyclonal and monoclonal antibodies. Clin Chim Acta 171 1 (1988) 1-10
269. Prasad M.R., Lovell M.A., Yatin M., Dhillon H., and Markesbery W.R. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 23 1 (1998) 81-88
270. Pratico D., Clark C.M., Lee V.M., Trojanowski J.Q., Rokach J., and FitzGerald G.A. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a non-invasive index of lipid peroxidation with disease severity. Ann Neurol 48 5 (2000) 809-812
271. Pratico D., and Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am J Med 109 7 (2000) 577-585
272. Pratico D., Iuliano L., Amerio G., Tang L.X., Rokach J., Sabatino G., et al. Down's syndrome is associated with increased 8,12-iso-iPF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann Neurol 48 5 (2000) 795-798
273. Pratico D., Lee V.M., Trojanowski J.Q., Rokach J., and FitzGerald G.A. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 12 15 (1998) 1777-1783
274. Pueschel S.M., Craig W.Y., and Haddow J.E. Lipids and lipoproteins in persons with Down's syndrome. J Intellect Disabil Res 36 4 (1992) 365-369
275. Pulido R., Jimenez-Escrig A., Orensanz L., Saura-Calixto F., and Jimenez-Escrig A. Study of plasma antioxidant status in Alzheimer's disease. Eur J Neurol 12 7 (2005) 531-535
276. 12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr 80 1 (2004) 114-122
277. Raji N.S., and Rao K.S. Trisomy 21 and accelerated aging: DNA-repair parameters in peripheral lymphocytes of Down's syndrome patients. Mech Ageing Dev 100 1 (1998) 85-101
278. Rebhorn H., and Pfeiffenberger H. In vitro life span and "unscheduled DNA synthesis" in subconfluent cultures and clones of trisomic and normal diploid fibroblasts. Mech Ageing Dev 18 3 (1982) 201-208
279. Reddy V.P., Obrenovich M.E., Atwood C.S., Perry G., and Smith M.A. Involvement of Maillard reactions in Alzheimer disease. Neurotox Res 4 3 (2002) 191-209
280. Reeves R.H., Baxter L.L., and Richtsmeier J.T. Too much of a good thing: mechanisms of gene action in Down syndrome. Trends Genet 17 2 (2001) 83-88
281. Reznick A.Z., and Packer L. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Meth Enzymol 233 (1994) 357-363
282. Richter T., Munch G., Luth H.J., Arendt T., Kientsch-Engel R., Stahl P., et al. Immunochemical crossreactivity of antibodies specific for "advanced glycation endproducts" with "advanced lipoxidation endproducts". Neurobiol Aging 26 4 (2005) 465-474
283. Rinaldi P., Polidori M.C., Metastasio A., Mariani E., Mattioli P., Cherubini A., et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 24 7 (2003) 915-919
284. Ringman J.M., Frautschy S.A., Cole G.M., Masterman D.L., and Cummings J.L. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2 2 (2005) 131-136
285. Riviere S., Birlouez-Aragon I., and Vellas B. Plasma protein glycation in Alzheimer's disease. Glycoconj J 15 10 (1998) 1039-1042
286. Roizen N.J., and Patterson D. Down's syndrome. Lancet 361 9365 (2003) 1281-1289
287. Rosenberg R.N., Baskin F., Fosmire J.A., Risser R., Adams P., Svetlik D., et al. Altered amyloid protein processing in platelets of patients with Alzheimer disease. Arch Neurol 54 2 (1997) 139-144
288. Rosenblatt D.S. Folate and homocysteine metabolism and gene polymorphisms in the etiology of Down syndrome. Am J Clin Nutr 70 4 (1999) 429-430
289. Ruitenberg A., van Swieten J.C., Witteman J.C., Mehta K.M., van Duijn C.M., Hofman A., et al. Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet 359 9303 (2002) 281-286
290. Salerno-Kennedy R., and Cashman K.D. Relationship between dementia and nutrition-related factors and disorders: an overview. Int J Vitam Nutr Res 75 2 (2005) 83-95
291. Salman M. Systematic review of the effect of therapeutic dietary supplements and drugs on cognitive function in subjects with Down syndrome. Eur J Paediatr Neurol 6 4 (2002) 213-219
292. Sanij E., Hatzistavrou T., Hertzog P., Kola I., and Wolvetang E.J. Ets-2 is induced by oxidative stress and sensitizes cells to H(2)O(2)-induced apoptosis: implications for Down's syndrome. Biochem Biophys Res Commun 287 4 (2001) 1003-1008
293. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336 17 (1997) 1216-1222
294. Sauer J., Tabet N., and Howard R. Alpha lipoic acid for dementia. Cochrane Database Syst Rev 1 (2004) CD004244
295. Savaskan E., Olivieri G., Meier F., Seifritz E., Wirz-Justice A., and Muller-Spahn F. Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity. Gerontology 49 6 (2003) 380-383
296. Sawa A., Oyama F., Cairns N.J., Amano N., and Matsushita M. Aberrant expression of bcl-2 gene family in Down's syndrome brains. Brain Res Mol Brain Res 48 1 (1997) 53-59
297. Scapagnini G., Butterfield D.A., Colombrita C., Sultana R., Pascale A., and Calabrese V. Ethyl ferulate, a lipophilic polyphenol, induces HO-1 and protects rat neurons against oxidative stress. Antioxid Redox Signal 6 5 (2004) 811-818
298. Scharf S., Mander A., Ugoni A., Vajda F., and Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 53 1 (1999) 197-201
299. Schneider L.S., DeKosky S.T., Farlow M.R., Tariot P.N., Hoerr R., and Kieser M. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res 2 5 (2005) 541-551
300. Schneider L.S., Pollock V.E., Zemansky M.F., Gleason R.P., Palmer R., and Sloane R.B. A pilot study of low-dose l-deprenyl in Alzheimer's disease. J Geriatr Psychiatry Neurol 4 3 (1991) 143-148
301. Schuchmann S., and Heinemann U. Increased mitochondrial superoxide generation in neurons from trisomy 16 mice: a model of Down's syndrome. Free Radic Biol Med 28 2 (2000) 235-250
302. Schuessel K., Leutner S., Cairns N.J., Muller W.E., and Eckert A. Impact of gender on upregulation of antioxidant defence mechanisms in Alzheimer's disease brain. J Neural Transmemb 111 9 (2004) 1167-1182
303. Schulz V. Ginkgo extract or cholinesterase inhibitors in patients with dementia: what clinical trials and guidelines fail to consider. Phytomedicine 10 Suppl 4 (2003) 74-79
304. Schupf N., Kapell D., Nightingale B., Rodriguez A., Tycko B., and Mayeux R. Earlier onset of Alzheimer's disease in men with Down syndrome. Neurology 50 4 (1998) 991-995
305. Schupf N., and Sergievsky G.H. Genetic and host factors for dementia in Down's syndrome. Br J Psychiatry 180 (2002) 405-410
306. Seidl R., Greber S., Schuller E., Bernert G., Cairns N., and Lubec G. Evidence against increased oxidative DNA-damage in Down syndrome. Neurosci Lett 235 3 (1997) 137-140
307. Seidl R., Schuller E., Cairns N., and Lubec G. Evidence against increased glycoxidation in patients with Alzheimer's disease. Neurosci Lett 232 1 (1997) 49-52
308. Selley M.L., Close D.R., and Stern S.E. The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol Aging 23 3 (2002) 383-388
309. Sen C.K., and Packer L. Antioxidant and redox regulation of gene transcription. FASEB J 10 7 (1996) 709-720
310. Seshadri S., Zornberg G.L., Derby L.E., Myers M.W., Jick H., and Drachman D.A. Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease. Arch Neurol 58 3 (2001) 435-440
311. Shapiro B.L. Whither Down syndrome critical regions?. Hum Genet 99 3 (1997) 421-423
312. Shigenaga M.K., Aboujaoude E.N., Chen Q., and Ames B.N. Assays of oxidative DNA damage biomarkers 8-oxo-2′-deoxyguanosine and 8-oxoguanine in nuclear DNA and biological fluids by high-performance liquid chromatography with electrochemical detection. Meth Enzymol 234 (1994) 16-33
313. Shuvaev V.V., Laffont I., Serot J.M., Fujii J., Taniguchi N., and Siest G. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol Aging 22 3 (2001) 397-402
314. Sikora E., Radziszewska E., Kmiec T., and Maslinska D. The impaired transcription factor AP-1 DNA binding activity in lymphocytes derived from subjects with some symptoms of premature aging. Acta Biochim Pol 40 2 (1993) 269-272
315. Sinha S. Antioxidant gene expression imbalance, aging and Down syndrome. Life Sci 76 12 (2005) 1407-1426
316. Siniscalchi A., Mancuso F., Gallelli L., Ferreri I.G., Biagio M.N., and De Sarro G. Increase in plasma homocysteine levels induced by drug treatments in neurologic patients. Pharmacol Res 52 5 (2005) 367-375
317. Smith C.D., Carney J.M., Starke-Reed P.E., Oliver C.N., Stadtman E.R., Floyd R.A., et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA 88 23 (1991) 10540-10543
318. Smith C.D., Carney J.M., Tatsumo T., Stadtman E.R., Floyd R.A., and Markesbery W.R. Protein oxidation in aging brain. Ann NY Acad Sci 663 (1992) 110-119
319. Smith M.A., Perry G., Richey P.L., Sayre L.M., Anderson V.E., Beal M.F., et al. Oxidative damage in Alzheimer's. Nature 382 6587 (1996) 120-121
320. Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S., and Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17 8 (1997) 2653-2657
321. Smith M.A., Sayre L.M., Anderson V.E., Harris P.L., Beal M.F., Kowall N., et al. Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. J Histochem Cytochem 46 6 (1998) 731-735
322. Smith M.A., Sayre L.M., Vitek M.P., Monnier V.M., and Perry G. Early AGEing and Alzheimer's. Nature 374 6520 (1995) 316
323. Smith M.A., Taneda S., Richey P.L., Miyata S., Yan S.D., Stern D., et al. Advanced Maillard reaction end-products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 91 12 (1994) 5710-5714
324. Sohal R.S., and Weindruch R. Oxidative stress, caloric restriction, and aging. Science 273 5271 (1996) 59-63
325. Srinivasan V., Pandi-Perumal S.R., Maestroni G.J., Esquifino A.I., Hardeland R., and Cardinali D.P. Role of melatonin in neurodegenerative diseases. Neurotox Res 7 4 (2005) 293-318
326. Stadelmann C., Bruck W., Bancher C., Jellinger K., and Lassmann H. Alzheimer disease: DNA fragmentation indicates increased neuronal vulnerability, but not apoptosis. J Neuropathol Exp Neurol 57 5 (1998) 56-464
327. Stadtman E.R. Protein oxidation and aging. Science 257 5074 (1992) 1220-1224
328. Steiner M.E., and Woods W.G. Normal formation and repair of gamma-radiation-induced single and double strand DNA breaks in Down syndrome fibroblasts. Mutat Res 95 2-3 (1982) 515-523
329. Stewart W.F., Kawas C., Corrada M., and Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48 3 (1997) 626-632
330. Stott D.J., MacIntosh G., Lowe G.D., Rumley A., McMahon A.D., Langhorne P., et al. Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. Am J Clin Nutr 82 6 (2005) 1320-1326
331. Su J.H., Deng G., and Cotman C.W. Neuronal DNA damage precedes tangle formation and is associated with up-regulation of nitrotyrosine in Alzheimer's disease brain. Brain Res 774 1-2 (1997) 193-199
332. Sultana R., Ravagna A., Mohmmad-Abdul H., Calabrese V., and Butterfield D.A. Ferulic acid ethyl ester protects neurons against amyloid beta- peptide(1-42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity. J Neurochem 92 4 (2005) 749-758
333. Szekely C.A., Thorne J.E., Zandi P.P., Ek M., Messias E., Breitner J.C., et al. Non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23 4 (2004) 159-169
334. Tabet N., Birks J., and Grimley E.J. Vitamin E for Alzheimer's disease. Cochrane Database Syst Rev 4 (2000) CD002854
335. Tabet N., Mantle D., Walker Z., and Orrell M. Endogenous antioxidant activities in relation to concurrent Vitamins A, C, and E intake in dementia. Int Psychogeriatr 14 1 (2002) 7-15
336. Tang M.X., Jacobs D., Stern Y., Marder K., Schofield P., Gurland B., et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348 9025 (1996) 429-432
337. Te Koppele J.M., Lucassen P.J., Sakkee A.N., Van Asten J.G., Ravid R., Swaab D.F., et al. 8OHdG levels in brain do not indicate oxidative DNA damage in Alzheimer's disease. Neurobiol Aging 17 6 (1996) 819-826
338. Tedgui A., and Mallat Z. Platelets in atherosclerosis: a new role for beta-amyloid peptide beyond Alzheimer's disease. Circ Res 90 11 (2002) 1145-1146
339. Teksen F., Sayli B.S., Aydin A., Sayal A., and Isimer A. Antioxidative metabolism in Down syndrome. Biol Trace Elem Res 63 2 (1998) 123-127
340. Teunissen C.E., de Vente J., Steinbusch H.W., and De Bruijn C. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging 23 4 (2002) 485-508
341. Thiel R., and Fowkes S.W. Can cognitive deterioration associated with Down syndrome be reduced?. Med Hypotheses 64 3 (2005) 524-532
342. Thomas T. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. Neurobiol Aging 21 2 (2000) 343-348
343. Thomas T., Thomas G., McLendon C., Sutton T., and Mullan M. beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380 6570 (1996) 168-171
344. Thome J., Gsell W., Rosler M., Kornhuber J., Frolich L., Hashimoto E., et al. Oxidative-stress associated parameters (lactoferrin, superoxide dismutases) in serum of patients with Alzheimer's disease. Life Sci 60 1 (1997) 13-19
345. Thome J., Munch G., Muller R., Schinzel R., Kornhuber J., Blum-Degen D., et al. Advanced glycation endproducts-associated parameters in the peripheral blood of patients with Alzheimer's disease. Life Sci 59 8 (1996) 679-685
346. Tobi S.E., Neary D., and Itzhaki R.F. Alkylation damage and repair in Alzheimer's disease lymphocytes. Gerontology 39 5 (1993) 241-251
347. Tokuda T., Fukushima T., Ikeda S., Sekijima Y., Shoji S., Yanagisawa N., et al. Plasma levels of amyloid beta proteins Aβ1-40 and Aβ1-42(43) are elevated in Down's syndrome. Ann Neurol 41 2 (1997) 271-273
348. Truelsen T., Thudium D., and Gronbaek M. Amount and type of alcohol and risk of dementia: the Copenhagen City Heart Study. Neurology 59 9 (2002) 1313-1319
349. Tuppo E.E., and Forman L.J. Free radical oxidative damage and Alzheimer's disease. J Am Osteopath Assoc 101 12 Suppl Pt 1 (2001) S11-S15
350. Tuppo E.E., Forman L.J., Spur B.W., Chan-Ting R.E., Chopra A., and Cavalieri T.A. Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease. Brain Res Bull 54 5 (2001) 565-568
351. Urakami K., Kataoka J., Okada A., Isoe K., Wakutani Y., Ji Y., et al. Analysis of amyloid precursor protein mRNAs in skin fibroblasts in Down's syndrome. Dementia 7 2 (1996) 82-85
352. Van Dongen M., van Rossum E., Kessels A., Sielhorst H., and Knipschild P. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Clin Epidemiol 56 4 (2003) 367-376
353. van Dongen M.C., van Rossum E., Kessels A.G., Sielhorst H.J., and Knipschild P.G. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc 48 10 (2000) 1183-1194
354. Varadarajan S., Yatin S., Aksenova M., and Butterfield D.A. Review: Alzheimer's amyloid β-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 130 2-3 (2000) 184-208
355. Vedder H., Anthes N., Stumm G., Wurz C., Behl C., and Krieg J.C. Estrogen hormones reduce lipid peroxidation in cells and tissues of the central nervous system. J Neurochem 72 6 (1999) 2531-2538
356. Vina J., Lloret A., Orti R., and Alonso D. Molecular bases of the treatment of Alzheimer's disease with antioxidants: prevention of oxidative stress. Mol Aspects Med 25 1-2 (2004) 117-123
357. Vitek M.P., Bhattacharya K., Glendening J.M., Stopa E., Vlassara H., Bucala R., et al. Advanced glycation end-products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 91 11 (1994) 4766-4770
358. Wang J., Xiong S., Xie C., Markesbery W.R., and Lovell M.A. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J Neurochem 93 4 (2005) 953-962
359. Wang J.Z., and Wang Z.F. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol Sin 27 1 (2006) 41-49
360. Wang P.N., Liao S.Q., Liu R.S., Liu C.Y., Chao H.T., Lu S.R., et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology 54 11 (2000) 2061-2066
361. Warner T.D., and Mitchell J.A. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 18 7 (2004) 790-804
362. Webber K.M., Casadesus G., Marlatt M.W., Perry G., Hamlin C.R., Atwood C.S., et al. Estrogen bows to a new master: the role of gonadotropins in Alzheimer pathogenesis. Ann NY Acad Sci 1052 (2005) 201-209
363. Weinreb O., Mandel S., Amit T., and Youdim M.B. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J Nutr Biochem 15 9 (2004) 506-516
364. Wettstein A. Cholinesterase inhibitors and Gingko extracts-are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least 6 months' duration. Phytomedicine 6 6 (2000) 393-401
365. Wisniewski K.E., Wisniewski H.M., and Wen G.Y. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 17 3 (1985) 278-282
366. Wolkowitz O.M., Kramer J.H., Reus V.I., Costa M.M., Yaffe K., Walton P., et al. DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study. Neurology 60 7 (2003) 1071-1076
367. Wu F.Y., Iijima K., Nishida A., and Higurashi M. Sister chromatid exchanges in the peripheral lymphocytes of newborns with Down syndrome after in vitro exposure to blue or green light. Mutat Res 367 4 (1996) 261-264
368. Xiang Z., Ho L., Valdellon J., Borchelt D., Kelley K., Spielman L., et al. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol Aging 23 3 (2002) 327-334
369. Yaffe K., Sawaya G., Lieberburg I., and Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 279 9 (1998) 688-695
370. Yan S.D., Chen X., Schmidt A.M., Brett J., Godman G., Zou Y.S., et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 91 16 (1994) 7787-7791
371. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280 7 (2005) 5892-5901
372. Yankner B.A., Duffy L.K., and Kirschner D.A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250 4978 (1990) 279-282
373. Yatin S.M., Varadarajan S., Link C.D., and Butterfield D.A. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid β-peptide (1-42). Neurobiol Aging 20 3 (1999) 325-330
374. Yoo B.C., Seidl R., Cairns N., and Lubec G. Heat-shock protein 70 levels in brain of patients with Down syndrome and Alzheimer's disease. J Neural Transmemb 57 Suppl (1999) 315-322
375. Yotti L.P., Glover T.W., Trosko J.E., and Segal D.J. Comparative study of X-ray and UV induced cytotoxicity, DNA repair, and mutagenesis in Down's syndrome and normal fibroblasts. Pediatr Res 14 2 (1980) 88-92
376. Yuan J., and Yankner B.A. Apoptosis in the nervous system. Nature 407 6805 (2000) 802-809
377. Zandi P.P., Anthony J.C., Hayden K.M., Mehta K., Mayer L., and Breitner J.C. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 59 6 (2002) 880-886
378. Zandi P.P., Anthony J.C., Khachaturian A.S., Stone S.V., Gustafson D., Tschanz J.T., et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 61 1 (2004) 82-88
379. Zatorska A., and Jozwiak Z. Involvement of glutathione and glutathione-related enzymes in the protection of normal and trisomic human fibroblasts against daunorubicin. Cell Biol Int 26 5 (2002) 383-391
380. Zemlan F.P., Thienhaus O.J., and Bosmann H.B. Superoxide dismutase activity in Alzheimer's disease: possible mechanism for paired helical filament formation. Brain Res 476 1 (1989) 160-162
381. Zhao B.L., Li X.J., He R.G., Cheng S.J., and Xin W.J. Scavenging effect of extracts of green tea and natural antioxidants on active oxygen radicals. Cell Biophys 14 2 (1989) 175-185
382. Zhu X., Raina A.K., Lee H.G., Casadesus G., Smith M.A., and Perry G. Oxidative stress signalling in Alzheimer's disease. Brain Res 1000 1-2 (2004) 32-39
383. Zhu X., Raina A.K., Perry G., and Smith M.A. Alzheimer's disease: the two-hit hypothesis. Lancet Neurol 3 4 (2004) 219-226
384. Zitnanova I., Korytar P., Aruoma O.I., Sustrova M., Garaiova I., Muchova J., et al. Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms?. Clin Chim Acta 341 1-2 (2004) 139-146